Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$55.30 USD

55.30
7,657,067

+0.98 (1.80%)

Updated Nov 4, 2024 03:55 PM ET

After-Market: $55.46 +0.16 (0.29%) 4:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study

Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.

    Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success

    Bristol-Myers' (BMY) phase III study evaluating Opdivo versus docetaxel was stopped earlier than expected as it met the primary endpoint.

      Celldex Begins Phase I Trial on Cancer Candidate CDX-1140

      Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.

        Cancer Space Update: Pfizer's Bavencio Fails in Phase III

        The only major development in the cancer space this week was the failure of Pfizer's (PFE) Bavencio in a phase III gastric cancer study.

          Arpita Dutt headshot

          Pharma Stock Roundup: Pfizer/Merck KGaA Drug Fails in Study, Teva CEO Announces Changes

          Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.

            3 Companies Competing to Gain Lead in Ovarian Cancer Market

            Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.

              Arpita Dutt headshot

              Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data

              Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.

                J&J Seeks Darzalex's Label Expansion in First-Line Setting

                Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.

                  Celldex (CLDX) Initiates Phase II Study on Cancer Candidate

                  Celldex (CLDX) enrolled the first patient in a phase II study on pipeline candidate, CDX-3379, to evaluate it in advanced head and neck squamous cell carcinoma patients.

                    Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

                    Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.

                      LabCorp Reports New Use of Agilent's Cancer Diagnostic Test

                      The testing of the clinical studies needed to approve PD-L1 IHC 28-8 pharmDx assay's new indications were performed at LabCorp's (LH) Center for Molecular Biology and Pathology laboratory.

                        Arpita Dutt headshot

                        Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

                        Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

                          Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II

                          Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.

                            Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion

                            Seattle Genetics received an approval from the FDA for an expanded indication of its drug Adcetris a month before its action date.

                              Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

                              Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

                                Sweta Killa headshot

                                Pharma ETFs Down Post Q3 Earnings

                                The string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month.

                                  Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up

                                  Nektar's (NKTR) earnings and revenues beat estimates in Q3. The company also raises its revenue guidance for the same period.

                                    Infinity (INFI) Q3 Loss Narrower than Expected, View Intact

                                    Infinity Pharmaceuticals (INFI) Q3 loss was narrower than estimates and the year-ago quarter loss.

                                      Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up

                                      Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.

                                        AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda

                                        AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.

                                          Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View

                                          Horizon Pharma (HZNP) Q3 results were driven by growth from the orphan and rheumatology business.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah

                                            It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.

                                              The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical

                                              The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical

                                                Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright

                                                Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright

                                                  Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright

                                                  Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright